Shanghai Runda Medical Technology Co., Ltd. (603108.SS)
CNY 17.57
(3.35%)
CNY 17.57
(3.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.11 Billion CNY | -38.91% |
| 2022 | 1.52 Billion CNY | 20.23% |
| 2021 | 1.32 Billion CNY | 16.19% |
| 2020 | 1.18 Billion CNY | 1.02% |
| 2019 | 1.15 Billion CNY | 16.87% |
| 2018 | 988.38 Million CNY | 49.45% |
| 2017 | 649.84 Million CNY | 100.68% |
| 2016 | 334.73 Million CNY | 43.68% |
| 2015 | 231.33 Million CNY | 32.13% |
| 2014 | 178.34 Million CNY | 30.52% |
| 2013 | 132.93 Million CNY | 32.37% |
| 2012 | 101.3 Million CNY | 38.06% |
| 2011 | 81.38 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 238.64 Million CNY | -9.78% |
| 2024 Q2 | 246.12 Million CNY | 39.99% |
| 2024 Q3 | 73.83 Million CNY | -68.17% |
| 2023 Q3 | 294.7 Million CNY | -2.75% |
| 2023 Q4 | 241.77 Million CNY | -17.96% |
| 2023 FY | - CNY | -38.91% |
| 2023 Q1 | 265.41 Million CNY | -41.76% |
| 2023 Q2 | 303.04 Million CNY | 14.18% |
| 2022 Q2 | 352.47 Million CNY | 61.14% |
| 2022 Q1 | 218.73 Million CNY | -8.3% |
| 2022 FY | - CNY | 20.23% |
| 2022 Q4 | 455.7 Million CNY | 10.64% |
| 2022 Q3 | 411.86 Million CNY | 16.85% |
| 2021 Q2 | 320.78 Million CNY | 15.68% |
| 2021 Q4 | 238.52 Million CNY | -24.14% |
| 2021 Q3 | 314.41 Million CNY | -1.99% |
| 2021 FY | - CNY | 16.19% |
| 2021 Q1 | 277.3 Million CNY | -17.09% |
| 2020 Q3 | 303.85 Million CNY | 43.76% |
| 2020 FY | - CNY | 1.02% |
| 2020 Q4 | 334.47 Million CNY | 10.08% |
| 2020 Q2 | 211.36 Million CNY | 40.25% |
| 2020 Q1 | 150.7 Million CNY | -42.59% |
| 2019 Q2 | 262.35 Million CNY | 19.37% |
| 2019 Q1 | 219.78 Million CNY | 6.57% |
| 2019 FY | - CNY | 16.87% |
| 2019 Q4 | 262.52 Million CNY | -14.04% |
| 2019 Q3 | 305.39 Million CNY | 16.41% |
| 2018 Q1 | 197.82 Million CNY | 10.93% |
| 2018 FY | - CNY | 49.45% |
| 2018 Q3 | 251.82 Million CNY | 8.44% |
| 2018 Q2 | 232.23 Million CNY | 17.39% |
| 2018 Q4 | 206.24 Million CNY | -18.1% |
| 2017 Q3 | 175.45 Million CNY | 17.03% |
| 2017 FY | - CNY | 100.68% |
| 2017 Q4 | 178.33 Million CNY | 1.64% |
| 2017 Q1 | 82.5 Million CNY | -13.9% |
| 2017 Q2 | 149.92 Million CNY | 81.71% |
| 2016 Q4 | 95.82 Million CNY | 36.9% |
| 2016 Q1 | 40.75 Million CNY | -32.92% |
| 2016 Q3 | 69.99 Million CNY | 15.74% |
| 2016 FY | - CNY | 43.68% |
| 2016 Q2 | 60.47 Million CNY | 48.38% |
| 2015 Q2 | 42.35 Million CNY | 29.6% |
| 2015 FY | - CNY | 32.13% |
| 2015 Q4 | 60.75 Million CNY | 32.07% |
| 2015 Q3 | 46 Million CNY | 8.63% |
| 2015 Q1 | 32.67 Million CNY | -43.51% |
| 2014 Q4 | 57.84 Million CNY | 64.93% |
| 2014 Q2 | 32.49 Million CNY | 41.76% |
| 2014 Q3 | 35.07 Million CNY | 7.92% |
| 2014 FY | - CNY | 30.52% |
| 2014 Q1 | 22.92 Million CNY | 0.0% |
| 2013 FY | - CNY | 32.37% |
| 2012 FY | - CNY | 38.06% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Joinn Laboratories(China)Co.,Ltd. | 639.51 Million CNY | -74.147% |
| WuXi AppTec Co., Ltd. | 14.16 Billion CNY | 92.14% |
| Autobio Diagnostics Co., Ltd. | 1.87 Billion CNY | 40.532% |
| Thalys Medical Technology Group Inc. | -23.79 Million CNY | 4780.704% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 1.33 Billion CNY | 16.369% |
| Chemclin Diagnostics Co., Ltd. | 219.33 Million CNY | -407.75% |